AtriCure (NASDAQ:ATRC) Hits New 1-Year High – Here’s What Happened

AtriCure, Inc. (NASDAQ:ATRC)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $44.80 and last traded at $44.6980, with a volume of 51505 shares. The stock had previously closed at $44.30.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, UBS Group decreased their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

AtriCure Price Performance

The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 215.67 and a beta of 1.20. The stock has a 50-day moving average of $33.91 and a two-hundred day moving average of $31.47.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the company posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current year.

Insiders Place Their Bets

In related news, Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the transaction, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director owned 40,518 shares in the company, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 47,246 shares of company stock worth $1,777,845 in the last quarter. Corporate insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATRC. Assenagon Asset Management S.A. acquired a new position in AtriCure in the second quarter worth approximately $1,744,000. F m Investments LLC acquired a new stake in AtriCure in the fourth quarter valued at approximately $2,872,000. Vanguard Group Inc. grew its position in AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock worth $193,993,000 after acquiring an additional 62,861 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of AtriCure during the 1st quarter worth $7,922,000. Finally, California State Teachers Retirement System raised its holdings in shares of AtriCure by 33.3% during the 1st quarter. California State Teachers Retirement System now owns 59,947 shares of the medical device company’s stock valued at $1,710,000 after purchasing an additional 14,987 shares in the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.